![Michal Fresser](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Michal Fresser has worked as the Chief Executive Officer at AXON Neuroscience SE since 2019.
He also currently holds a position as Director at AXON HOLDING SE.
Postes actifs de Michal Fresser
Sociétés | Poste | Début |
---|---|---|
AXON Neuroscience SE
![]() AXON Neuroscience SE BiotechnologyHealth Technology Part of Istrokapital SE, AXON Neuroscience SE is a Cypriot clinical stage biotech company that specializes in peptide-based vaccines for treating fatal human diseases. The company is based in Larnaca, Cyprus. AXON Neuroscience has the single biggest team in the world dedicated exclusively to tau research in relation to treating Alzheimer's disease, with over 60 scientists and 15 senior scientific leaders. The company's lead vaccine, AADvac1, is the most clinically-advanced tau therapy in development for treating and preventing Alzheimer's disease. AXON Neuroscience has extensive knowledge in producing safe and immunogenic vaccines and well-established scalable technology, which allowed it to move quickly in creating its novel peptide vaccine against COVID-19. The company was founded in 1999 by Michal Novak. Michal Fresser has been the CEO of the company since 2013. | Directeur Général | 01/08/2019 |
AXON HOLDING SE
![]() AXON HOLDING SE Financial ConglomeratesFinance AXON HOLDING SE engages in holding of investments and provision of financing services to related companies. The company was founded on October 23, 2014 and is headquartered in Larnaca, Cyprus. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
AXON Neuroscience SE
![]() AXON Neuroscience SE BiotechnologyHealth Technology Part of Istrokapital SE, AXON Neuroscience SE is a Cypriot clinical stage biotech company that specializes in peptide-based vaccines for treating fatal human diseases. The company is based in Larnaca, Cyprus. AXON Neuroscience has the single biggest team in the world dedicated exclusively to tau research in relation to treating Alzheimer's disease, with over 60 scientists and 15 senior scientific leaders. The company's lead vaccine, AADvac1, is the most clinically-advanced tau therapy in development for treating and preventing Alzheimer's disease. AXON Neuroscience has extensive knowledge in producing safe and immunogenic vaccines and well-established scalable technology, which allowed it to move quickly in creating its novel peptide vaccine against COVID-19. The company was founded in 1999 by Michal Novak. Michal Fresser has been the CEO of the company since 2013. | Health Technology |
AXON HOLDING SE
![]() AXON HOLDING SE Financial ConglomeratesFinance AXON HOLDING SE engages in holding of investments and provision of financing services to related companies. The company was founded on October 23, 2014 and is headquartered in Larnaca, Cyprus. | Finance |